JAK Inhibitors and Targeted Small-Molecule Immunosuppressants

Apremilast inhibits phosphodiesterase 4 (PDE4), the predominant phosphodiesterase isoenzyme in immune cells. PDE4 hydrolyzes cyclic AMP (cAMP) to inactive 5-AMP; its inhibition raises intracellular cAMP levels, activating protein kinase A and downstream pathways that suppress production of tumor necrosis factor-alpha, interleukin-17, interleukin-23, and interferon-gamma while increasing the anti-inflammatory cytokine interleukin-10. The mechanism produces anti-inflammatory but not broadly immunosuppressive effects. Apremilast is approved for moderate-to-severe plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behcet's disease. Its efficacy is more modest than biologics in psoriasis (PASI 75 response approximately 30 to 40% versus 60 to 80% for biologic agents) but it carries no serious infection, malignancy, or cardiovascular risk signals. The main adverse effects are gastrointestinal — nausea and diarrhea in up to 30% of patients in the first four to six weeks, managed with a five-day dose titration schedule at initiation. Apremilast is also metabolized by CYP3A4, so strong inducers such as rifampin reduce its exposure substantially and the combination is contraindicated.

Sphingosine-1-phosphate (S1P) is a bioactive lipid that maintains a plasma-to-lymph-node gradient driving lymphocyte egress from lymphoid organs into the bloodstream via S1P receptor 1 on lymphocyte surfaces. Ozanimod is a selective S1P receptor 1 and S1P receptor 5 modulator that causes internalization and downregulation of S1P receptor 1, functionally trapping mature lymphocytes within lymph nodes and Peyer's patches and thereby reducing lymphocyte trafficking to inflamed tissues. The resulting peripheral lymphopenia is dose-dependent and fully reversible upon discontinuation. Ozanimod is approved for relapsing multiple sclerosis and moderate-to-severe ulcerative colitis.

S1P modulators carry class-specific safety considerations. First-dose bradycardia and atrioventricular block can occur, requiring cardiac monitoring for at least six hours after the first dose in patients with pre-existing cardiac conduction abnormalities or concurrent antiarrhythmic use. Macular edema requires an ophthalmic examination before initiation and in any patient who develops visual symptoms. Coadministration with monoamine oxidase inhibitors is contraindicated due to risk of serotonin syndrome through ozanimod's active metabolites. Herpes zoster reactivation risk is increased and Shingrix vaccination is recommended before initiation.

Deucravacitinib represents a fundamentally distinct approach to JAK family inhibition. Rather than competing with ATP at the catalytic kinase domain (JH1) as conventional JAK inhibitors do, deucravacitinib binds the regulatory pseudokinase domain (JH2) of TYK2, stabilizing it in an autoinhibited conformation. The JH2 domains of the four JAK isoforms are substantially less conserved than their JH1 kinase domains, so this allosteric mechanism confers greater than 2,000-fold selectivity for TYK2 over JAK1, JAK2, and JAK3. By selectively inhibiting TYK2, deucravacitinib suppresses interleukin-12 and interleukin-23 signaling (driving Th1 and Th17 differentiation in psoriasis) and type I interferon signaling, without meaningfully affecting JAK1- or JAK2-dependent hematopoietic and metabolic functions. Deucravacitinib is approved for moderate-to-severe plaque psoriasis; in the POETYK PSO-1 and PSO-2 trials it achieved PASI 75 in approximately 58 to 62% of patients at week 16, significantly superior to apremilast, without the class-wide black box warnings of JAK inhibitors. It is positioned between apremilast and biologic agents for psoriasis and does not require prior TNF inhibitor failure.

Vedolizumab is a humanized monoclonal antibody — though administered parenterally, it is covered here because its gut-selective mechanism contrasts directly with the systemic oral agents used in inflammatory bowel disease. Vedolizumab blocks the alpha-4/beta-7 integrin heterodimer on lymphocytes, preventing binding to mucosal addressin cell adhesion molecule 1 on gut endothelium and selectively blocking lymphocyte trafficking into the gut lamina propria without affecting systemic lymphocyte migration. This gut-selective mechanism produces a favorable systemic safety profile with no meaningful systemic immunosuppression, no requirement for tuberculosis screening equivalent to TNF inhibitors, and no signals for increased malignancy or cardiovascular events. The trade-off is a slower onset of action — maximal benefit often not apparent until 12 to 14 weeks — making it less suitable when rapid response is needed. Vedolizumab is approved for moderate-to-severe ulcerative colitis and Crohn's disease and is preferred in older patients and those with prior malignancy or recurrent infections where systemic immunosuppression carries higher risk.

For treatment sequencing in ulcerative colitis, current guidelines position TNF inhibitors (infliximab, adalimumab, golimumab) or vedolizumab as first-line biologic options, with upadacitinib, tofacitinib, and ozanimod available after TNF inhibitor failure or for patients preferring oral therapy. Tofacitinib and upadacitinib act more rapidly than vedolizumab or ozanimod, making them preferred when urgency of response is high. In Crohn's disease, upadacitinib is the only approved JAK inhibitor; risankizumab and ustekinumab are biologic alternatives. Biologics and small molecules are not combined in clinical practice due to additive immunosuppression without established evidence of benefit.